

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Supplemental Table 5. Tumor Biomarkers

Cohort	Type of Cancer	Best Change in Tumor Size	PD-L1^a Pre-treatment	TIM-3^b Pre-treatment	CD8^b Pre-treatment	CD8^b Post-treatment
A1	Rectal cancer	37.7%	<1	65	77	73
	Non-small cell lung cancer	-29.6%	90 ^c	NA ^c	NA ^c	NA
	Breast cancer	15.7%	<1 ^c	8 ^c	22 ^c	43
A2	Non-small cell lung cancer	30%	<1	25	97	120
	Breast cancer	3.8%	<1	3	41	NA
	Breast cancer	22.3%	<1	4	15	1
A3	Ovarian cancer	6.9%	<1	13	23	26
	Desmoplastic small round cell tumor	8.4%	<1	0	0	2
	Peritoneal sarcoma	11.0%	<1	0	0	3
A4	Rectal cancer	30.6%	2	5	29	73
	Ductal adenocarcinoma of pancreas	14.2%	<1	1	9	NA
	Breast cancer	NE	<1	6	30	NA

^a PD-L1 expression results are reported as tumor proportional score (TPS).

^b TIM-3 and CD8 expression results are reported as number of positive cells per high power microscopic field.

^c Tumor markers were assessed by IHC in archival tissue samples at baseline for this patient.

Abbreviations: NA, not applicable; NE, non evaluable; PD-L1, programmed death ligand 1; TIM-3, T cell immunoglobulin and mucin-domain-containing molecule-3.

Note: Tumor biomarkers were measured in fresh samples unless otherwise indicated.